Ignace B. Vergote, MD, PhD

home / authors / ignace-b-vergote-md-phd

Articles

Ignace B. Vergote, MD, PhD

Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

Ignace B. Vergote, MD, PhD
January 8th 2024

Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).

Read More

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

Caroline Seymour;Paolo Tarantino, MD;Jacob Sands, MD;Yelena Y. Janjigian, MD;Ignace B. Vergote, MD, PhD
October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Read More

Dr. Vergote on the Need to Develop Novel Therapies in Endometrial Cancer

Dr. Vergote on the Need to Develop Novel Therapies in Endometrial Cancer

Ignace B. Vergote, MD, PhD
June 11th 2020

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data